Literature DB >> 19003523

Crosstalk between IGF1R and estrogen receptor signaling in breast cancer.

Dedra H Fagan1, Douglas Yee.   

Abstract

After the discovery that depriving certain breast tumors of estrogen promoted tumor regression, therapeutic strategies aimed at depriving tumors of this hormone were developed. The tumorigenic properties of estrogen are regulated through the estrogen receptor-alpha (ER), making understanding the mechanisms that activate this receptor highly relevant. In addition to estrogen activating the ER, other growth factor pathways, such as the insulin-like growth factors (IGFs), can activate the ER. This review will examine the interaction between these two pathways. Estrogen can activate the growth stimulatory properties of the IGF pathway via ER's genomic and non-genomic functions. Further, blockade of ER function can inhibit IGF-mediated mitogenesis and blocking IGF action can inhibit estrogen stimulation of breast cancer cells. Collectively, these observations suggest that the two growth regulatory pathways are tightly linked and a more thorough understanding of the mechanism of this crosstalk could lead to improved therapeutic strategies in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19003523     DOI: 10.1007/s10911-008-9098-0

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  74 in total

1.  Commercial interest waxes for IGF-1 blockers.

Authors:  Randy Osborne
Journal:  Nat Biotechnol       Date:  2008-07       Impact factor: 54.908

Review 2.  Estrogen receptor: current understanding of its activation and modulation.

Authors:  C K Osborne; R Schiff; S A Fuqua; J Shou
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

3.  Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.

Authors:  F Frasca; G Pandini; P Scalia; L Sciacca; R Mineo; A Costantino; I D Goldfine; A Belfiore; R Vigneri
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

4.  A 13 bp palindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor.

Authors:  L Klein-Hitpass; G U Ryffel; E Heitlinger; A C Cato
Journal:  Nucleic Acids Res       Date:  1988-01-25       Impact factor: 16.971

5.  Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta.

Authors:  G B Tremblay; A Tremblay; N G Copeland; D J Gilbert; N A Jenkins; F Labrie; V Giguère
Journal:  Mol Endocrinol       Date:  1997-03

6.  Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status.

Authors:  J A Figueroa; J G Jackson; W L McGuire; R F Krywicki; D Yee
Journal:  J Cell Biochem       Date:  1993-06       Impact factor: 4.429

7.  Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.

Authors:  A V Lee; J G Jackson; J L Gooch; S G Hilsenbeck; E Coronado-Heinsohn; C K Osborne; D Yee
Journal:  Mol Endocrinol       Date:  1999-05

Review 8.  Basic guide to the mechanisms of antiestrogen action.

Authors:  J I MacGregor; V C Jordan
Journal:  Pharmacol Rev       Date:  1998-06       Impact factor: 25.468

9.  Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase.

Authors:  S Kato; H Endoh; Y Masuhiro; T Kitamoto; S Uchiyama; H Sasaki; S Masushige; Y Gotoh; E Nishida; H Kawashima; D Metzger; P Chambon
Journal:  Science       Date:  1995-12-01       Impact factor: 47.728

10.  The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.

Authors:  Joanna Lisztwan; Astrid Pornon; Bin Chen; Shiuan Chen; Dean B Evans
Journal:  Breast Cancer Res       Date:  2008-07-08       Impact factor: 6.466

View more
  74 in total

Review 1.  Molecular therapy of breast cancer: progress and future directions.

Authors:  Sheng-Xiang Lin; Jiong Chen; Mausumi Mazumdar; Donald Poirier; Cheng Wang; Arezki Azzi; Ming Zhou
Journal:  Nat Rev Endocrinol       Date:  2010-07-20       Impact factor: 43.330

2.  Tumorigenicity of MCF-7 human breast cancer cells lacking the p38α mitogen-activated protein kinase.

Authors:  Rhone A Mendoza; Emily E Moody; Marlene I Enriquez; Sylvia M Mejia; Gudmundur Thordarson
Journal:  J Endocrinol       Date:  2010-10-25       Impact factor: 4.286

3.  Interactions between IGF-I, estrogen receptor-α (ERα), and ERβ in regulating growth/apoptosis of MCF-7 human breast cancer cells.

Authors:  Rhone A Mendoza; Marlene I Enriquez; Sylvia M Mejia; Emily E Moody; Gudmundur Thordarson
Journal:  J Endocrinol       Date:  2010-10-25       Impact factor: 4.286

4.  A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen.

Authors:  Boryana M Eastman; Minji Jo; Drue L Webb; Shinako Takimoto; Steven L Gonias
Journal:  Cell Signal       Date:  2012-05-19       Impact factor: 4.315

5.  Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer.

Authors:  Robert T Dauchy; Shulin Xiang; Lulu Mao; Samantha Brimer; Melissa A Wren; Lin Yuan; Muralidharan Anbalagan; Adam Hauch; Tripp Frasch; Brian G Rowan; David E Blask; Steven M Hill
Journal:  Cancer Res       Date:  2014-08-01       Impact factor: 12.701

6.  Multivariate hypergeometric similarity measure.

Authors:  Chanchala D Kaddi; R Mitchell Parry; May D Wang
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2013 Nov-Dec       Impact factor: 3.710

7.  Estrogen up-regulates ATBF1 transcription but causes its protein degradation in estrogen receptor-alpha-positive breast cancer cells.

Authors:  Xue-Yuan Dong; Peng Guo; Xiaodong Sun; Qunna Li; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2011-03-02       Impact factor: 5.157

Review 8.  Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.

Authors:  Jennifer R Ribeiro; Richard N Freiman
Journal:  J Steroid Biochem Mol Biol       Date:  2014-02-22       Impact factor: 4.292

9.  AKT regulates BRCA1 stability in response to hormone signaling.

Authors:  Andrew C Nelson; Traci R Lyons; Christian D Young; Kirk C Hansen; Steven M Anderson; Jeffrey T Holt
Journal:  Mol Cell Endocrinol       Date:  2010-01-18       Impact factor: 4.102

Review 10.  Osteoarthritis associated with estrogen deficiency.

Authors:  Jorge A Roman-Blas; Santos Castañeda; Raquel Largo; Gabriel Herrero-Beaumont
Journal:  Arthritis Res Ther       Date:  2009-09-21       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.